Melys AFS, Ltd. is a private company founded to develop noninvasive monitoring of patients with Atrial Fibrillation (AF).
Stroke Prevention through Atrial Fibrillation Monitoring
Chronic AF is the most common arrhythmia seen in medical practice. AF causes increased patient morbidity and mortality and adds significantly to the burden of health care costs. The prevalence of AF increases with age, as do the associated risks of stroke and heart disease.
Once identified, AF can be treated to minimize risks associated with AF, such as stroke. Detection of AF and proper patient monitoring as part of any treatment regime are key preventative measures.
Melys AFS has developed an instrument that provides a cost-effective and non-invasive method of detecting and monitoring AF.